Incidence of Hyperpigmentation in Black Patients With Multiple Myeloma Treated With Immunomodulatory Drugs
NCT ID: NCT06160167
Last Updated: 2024-08-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
4204 participants
OBSERVATIONAL
2023-10-01
2024-08-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma
NCT01709162
Ipilimumab + Temozolomide in Metastatic Melanoma
NCT01119508
A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma
NCT02644967
A Long Term Follow up Study for Patients Who Previously Took Part in the Phase I Study IMM-101-001
NCT01559818
Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab
NCT01515189
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Participants with MM treated with IMiDs
IMiD treatment
Participants with MM treated with IMiDs
Participants with MM not treated with IMiDs
No IMiD treatment
Participants with MM not treated with IMiDs
Participants with MM treated with systemic therapy
Systemic therapy
Participants with MM treated with systemic therapy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
IMiD treatment
Participants with MM treated with IMiDs
No IMiD treatment
Participants with MM not treated with IMiDs
Systemic therapy
Participants with MM treated with systemic therapy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants with new diagnosis of MM as defined by:
* ICD-9-CM: 203.0x and/or ICD-10-CM: C90.0x or C90 during the study period
* At least two documented clinical visits for MM on different days and occurring on or after January 1, 2011
* Participants who received at least one systemic MM therapy on or after initial MM diagnosis
* Participants who did not receive clinical study drug at any time during the observation period
* Participants with race information
Exclusion Criteria
* Patients in more than one race category (mix race), missing race, unknown race, and "other" race
* Patients diagnosed with the following hematological cancers on or prior to the index date:
* myelodysplastic syndromes (ICD-9: 238.74, 238.75; ICD-10: D46.xx)
* mantle cell lymphoma (ICD-9: 200.4x, ICD-10: C83.1x)
* follicular lymphoma (ICD-9: 202.0x, ICD-10: C82.xx)
* marginal zone lymphoma (ICD-9: 200.3x, ICD-10: C83.4x)
* Patients with evidence of skin hyperpigmentation (ICD-9: 709.00, 709.09; ICD-10: L81.0, L81.1, L81.4, L81.8) on or prior to the index date
* 709.00 Dyschromia, unspecified
* 709.09 Other dyschromia
* L81.0 Post inflammatory hyperpigmentation
* L81.1 Chloasma/melasma
* L81.4 Other melanin hyperpigmentation
* L81.8 Other specified disorders of pigmentation
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol Myers-Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Flatiron Health Oncology Database
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
BMS Clinical Trial Information
FDA Safety Alerts and Recalls
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CA078-1007
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.